Transce3nd’s Novo Nordisk NVO Stock Holding History

Transce3nd’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-65	Closed	-$4.49K	–	808
2025 Q2	$4.49K	Sell	65 -324	-83%	-$22K	﹤0.01%	766
2025 Q1	$27K	Hold	389	–	–	0.01%	385
2024 Q4	$33.5K	Buy	+389	New	+$42.1K	0.01%	453

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Transce3nd's NVO Position: Q3 2025 in Review

Transce3nd sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 65 shares — an estimated $4.49K sold.

Transce3nd first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $33.5K in Q4 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Transce3nd reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 65 Novo Nordisk shares in Q3 2025, an estimated $4.49K.
Transce3nd first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
Transce3nd's Novo Nordisk position peaked at $33.5K in Q4 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.